You are here: Industry Insights > InnoCare

News List

Latest Data of InnoCare’s Orelabrutinib Presented at the European Society for Medical Oncology (ESMO) Congress 2024 PharmaSources
September 14, 2024
Latest data of InnoCare’s (HKEX: 09969; SSE: 688428) orelabrutinib were presented at the European Society for Medical Oncology (ESMO) Congress 2024.
InnoCare Announces First Prescription of Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma Under Greater Bay Area’s Early Access Program PharmaSources
January 23, 2024
The early access program of the Greater Bay Area allows designated medical institutions in the area to access drugs and medical devices that have been approved by regulatory authorities for marketing in Hong Kong or Macao.
InnoCare Announces Phase II Study Results of TYK2 Inhibitor ICP-332 Meet Primary Endpoint in Patients with Atomic Dermatitis PharmaSources
January 17, 2024
InnoCare Pharma announced today that phase II clinical study results of novel TYK2 inhibitor ICP-332 met primary endpoint in adult patients with moderate-to-severe atopic dermatitis.
InnoCare to Present at the 42nd Annual J.P. Morgan Healthcare Conference PharmaSources
December 28, 2023
InnoCare Pharma announced today that Dr. Jasmine Cui, Co-founder, Chairwoman and CEO, will present at the 42nd Annual J.P. Morgan Healthcare Conference, at 08:30 AM, January 10, 2024, U.S.
InnoCare Appoints Xin Fu as Chief Financial Officer PharmaSources
December 18, 2023
InnoCare Pharma, announced today that the Company appointed Mr. Xin Fu, who has extensive finance-related experience, as the Chief Financial Officer.
InnoCare Announces Inclusion of Orelabrutinib’s New Indication in China National Reimbursement Drug List 2023 PharmaSources
December 14, 2023
InnoCare Pharma announced today the inclusion of new indication of BTK inhibitor orelabrutinib in the updated National Reimbursement Drug List 2023.
Latest Data of InnoCare’s Oncology Pipelines Presented at the 65th Annual Meeting of ASH PharmaSources
December 11, 2023
InnoCare Pharma announced today that the latest data from InnoCare's oncology studies were presented at the 65th American Society of Hematology (ASH) Annual Meeting.
Study Result of Orelabrutinib in Patients with r/r MZL Published by American Journal of Hematology PharmaSources
September 13, 2023
American Journal of Hematology recently published the study result of BTK (Bruton Tyrosine Kinase) inhibitor orelabrutinib in patients with relapsed or refractory (r/r) Marginal Zone Lymphoma (MZL).
InnoCare Announces First Psoriasis Patient Dosed in Clinical Trial of TYK2 Allosteric Inhibitor ICP-488 in China PharmaSources
July 05, 2023
On July 5, 2023,InnoCare Pharma announced the first psoriasis patient has been dosed in clinical trial of the Company’s TYK2 JH2 allosteric inhibitor ICP-488 in China.
Latest Data of InnoCare’s Orelabrutinib Presented at the 17th International Conference on Malignant Lymphoma (ICML) PharmaSources
June 16, 2023
On June 16, 2023,InnoCare Pharma, a leading biopharmaceutical company, today announced the latest clinical data of its Bruton Tyrosine Kinase inhibitor orelabrutinib at the 17th International Conference on Malignant Lymphoma.

Previous page 1 2 3 4 5 6 7 Next page